Phase II trial of gemcitabine/carboplatin followed by paclitaxel in patients with performance status = 2,3 or other significant co-morbidity (HIV infection or s/p organ transplantation) in advanced non-small cell lung cancer

• Published in: Lung cancer (Amsterdam, Netherlands) Netherlands), 2008-07, Vol.61 (1), p.61-66
• Main Authors: Bridges, Benjamin B, Thomas, Leno, Hausner, Petr F, Doyle, L. Austin, Bedor, Michelle, Smith, Ruth, Brahmer, Julie, Edelman, Martin J
• Format: Article
• Language: English
• Subjects: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Biological and medical sciences; Carboplatin - administration & dosage; Carboplatin - adverse effects; Carcinoma, Non-Small-Cell Lung - drug therapy; Carcinoma, Non-Small-Cell Lung - epidemiology; Chemotherapy; Clinical trial; Comorbidity; Deoxycytidine - administration & dosage; Deoxycytidine - adverse effects; Deoxycytidine - analogs & derivatives; Female; Hematology, Oncology and Palliative Medicine; HIV Infections - epidemiology; Human viral diseases; Humans; Immunocompromised; Immunodeficiencies; Immunodeficiencies. Immunoglobulinopathies; Immunopathology; Infectious diseases; Kaplan-Meier Estimate; Lung cancer; Lung Neoplasms - drug therapy; Lung Neoplasms - epidemiology; Male; Medical sciences; Middle Aged; Organ Transplantation; Paclitaxel - administration & dosage; Paclitaxel - adverse effects; Pneumology; Poor performance status; Pulmonary/Respiratory; Tumors; Tumors of the respiratory system and mediastinum; Viral diseases; Viral diseases of the lymphoid tissue and the blood. Aids
• ISSN: 0169-5002; 1872-8332
• DOI: 10.1016/j.lungcan.2007.11.009

Summary Introduction The role of chemotherapy in patients with advanced non-small cell lung cancer and poor performance status or who have HIV disease or organ transplantation is unclear. While survival appears to be enhanced, serious toxicity may occur. We evaluated the efficacy of sequential, dose attenuated carboplatin/gemcitabine followed by paclitaxel in patients with PS = 2,3, HIV infection or after solid organ transplantation. Patients and methods Chemotherapy naive patients with PS 2,3 or who were HIV positive or post solid organ transplantation were eligible. Treatment consisted of gemcitabine: 1000 mg/m2 d 1,8 carboplatin: AUC = 5 d 1 q 21d × 2 followed by paclitaxel 80 mg/m2 q wk × 6 followed by a 2 week break and then repeated until progression. Results 47 patients were entered. Stage IIIb/IV: 8/39, PS 2/3 = 26/19, HIV infection = 2, solid organ transplantation = 2. 12 (25%) had brain metastases. Thirty-nine patients completed two cycles of carboplatin/gemcitabine and 29 pts received at least one cycle of paclitaxel. Overall response rate was 19% (95% CI 1.2–31.7%). Median event free, overall and 1-year survivals were 3.3 months, 5.8 months and 8.4%. Toxicity was moderate with 19% experiencing grade 4 neutropenia (11% with febrile neutropenia). Conclusions Sequential carboplatin/gemcitabine to paclitaxel is well tolerated and active in this population. The survival seen is comparable to that of other regimens utilized in PS = 2 patients with superior tolerability however, the prognosis for these patients is very poor even with treatment. This is the first trial to prospectively evaluate chemotherapy for patients with HIV disease or organ transplantation and NSCLC.